Psoriatic arthritis joint fluids are characterized by CD8 and CD4 T cell clonal expansions appear antigen driven
about
Psoriatic arthritis: pathogenesis and novel immunomodulatory approaches to treatmentOptimal management of dactylitis in patients with psoriatic arthritisDisease mechanisms in psoriasis and psoriatic arthritis.Pathways of cell activation in spondyloarthropathies.Interleukin 15 primes natural killer cells to kill via NKG2D and cPLA2 and this pathway is active in psoriatic arthritis.Circulating activated and effector memory T cells are associated with calcification and clonal expansions in bicuspid and tricuspid valves of calcific aortic stenosis.Regulatory CD8+ T cells fine-tune the myelin basic protein-reactive T cell receptor V beta repertoire during experimental autoimmune encephalomyelitisEarly effects of tumour necrosis factor alpha blockade on skin and synovial tissue in patients with active psoriasis and psoriatic arthritis.Concepts of pathogenesis in psoriatic arthritis: genotype determines clinical phenotype.Interactions of the innate and adaptive arms of the immune system in the pathogenesis of spondyloarthritisEctopic lymphoid neogenesis in psoriatic arthritis.Immunopathology of psoriasis and psoriatic arthritisPsoriasis and psoriatic arthritis: separate or one and the same?T cells in psoriatic arthritis.Psoriatic arthritis: from pathogenesis to therapy.The microbiome and psoriatic arthritis.Psoriatic arthritis under a proteomic spotlight: application of novel technologies to advance diagnosis and management.Contribution of the IL-17 Pathway to Psoriasis and Psoriatic Arthritis.A naive-like population of human CD1d-restricted T cells expressing intermediate levels of promyelocytic leukemia zinc finger.Synovial tissue response to treatment in psoriatic arthritis.Angiogenic and inflammatory properties of psoriatic arthritis.T Cell Receptor Profiling in Type 1 Diabetes.Alefacept treatment in psoriatic arthritis: reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis.Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial.Reduction of synovial sublining layer inflammation and proinflammatory cytokine expression in psoriatic arthritis treated with methotrexate.Psoriasis as initiator or amplifier of the systemic inflammatory march: impact on development of severe vascular events and implications for treatment strategy.Clinical Features of Psoriatic Arthritis: a Comprehensive Review of Unmet Clinical Needs.Role of the IL-23/IL-17 Axis in Psoriasis and Psoriatic Arthritis: The Clinical Importance of Its Divergence in Skin and Joints.Current treatment options for psoriatic arthritis: spotlight on abatacept.Psoriasis
P2860
Q24813979-007D7238-B579-4263-BE45-5B53946089C2Q28072557-2F79827B-3484-4848-A856-A2513E2B07DBQ34374510-0753D176-162D-44D1-9215-013AD816D075Q34374521-1D431EE3-0BA7-4626-B46B-CD3941C339F7Q35006277-B0F3AAC9-768A-4E6F-BC39-63548D4258E3Q35091286-86462020-DEB5-45BD-BC50-27B7291DED59Q35168156-C5222DF3-5A30-4297-BDE1-E299863AE32AQ35554321-2A9FA1D0-5157-4D22-86C6-9ADCDE93469CQ35577152-C38EB429-563C-4693-9396-8DD632A701F2Q35694939-2F57A2F3-E123-4C75-8982-4BDC96D65D27Q35953359-389EC76E-4025-4545-8B55-82F3245C26FBQ36040037-21D2E6DD-7270-4899-B24D-6CB77527087BQ36921661-F6A0C0F0-24FA-4289-86EB-BB444BC25330Q37051496-B3C1062A-7E05-4DD2-8DC2-19F6794CEC70Q37397676-010B3F2A-4CE7-43D7-B13D-E3B26AC93C26Q38182899-5FFFB082-BBC9-4AE1-ADDE-9F0591ACA034Q38431361-A5AD1D17-E97A-41EE-85F8-D990933BACB1Q38553845-E87270A1-50EA-4C53-907B-22E9D5F0D6F7Q39532148-2F7FB018-AD29-4DC6-A903-3D9568BEB89AQ40576433-0847380C-B559-499F-B236-4E3579812CCFQ42156810-3FEA7E76-A1FC-47EC-8008-FD6CF4E1C0FEQ42374922-E6071441-8DF7-46AA-BCF3-F54C4B25F0AEQ42685943-6E89D330-C701-4653-9F6E-D66EC5D0F1F1Q44930031-4E2FD25F-047B-4AEE-896F-F9637DEAC3F2Q45099941-EBDFE72A-0AAC-489F-A5E4-CA7BBA67F91DQ46838241-A5A7743C-58FF-4EA9-835A-AB895EC6DAC5Q48339070-AC778875-83E3-402C-86C3-3DBA668F9B1BQ50099588-049E9B8A-808A-48DA-B22F-03C5089D39A7Q55318901-06CCDC63-5F80-4918-8DE9-E81A1898A7E1Q58235909-3DD03BB1-266B-461F-8357-323B9F643C32
P2860
Psoriatic arthritis joint fluids are characterized by CD8 and CD4 T cell clonal expansions appear antigen driven
description
2001 nî lūn-bûn
@nan
2001 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Psoriatic arthritis joint flui ...... pansions appear antigen driven
@ast
Psoriatic arthritis joint flui ...... pansions appear antigen driven
@en
Psoriatic arthritis joint flui ...... pansions appear antigen driven
@nl
type
label
Psoriatic arthritis joint flui ...... pansions appear antigen driven
@ast
Psoriatic arthritis joint flui ...... pansions appear antigen driven
@en
Psoriatic arthritis joint flui ...... pansions appear antigen driven
@nl
prefLabel
Psoriatic arthritis joint flui ...... pansions appear antigen driven
@ast
Psoriatic arthritis joint flui ...... pansions appear antigen driven
@en
Psoriatic arthritis joint flui ...... pansions appear antigen driven
@nl
P2093
P1476
Psoriatic arthritis joint flui ...... pansions appear antigen driven
@en
P2093
B Bresnihan
K S Peterson
O M FitzGerald
P J Costello
R J Winchester
S A Curran
P304
P356
10.4049/JIMMUNOL.166.4.2878
P407
P577
2001-02-15T00:00:00Z